Senzime AB (publ) (SNZZF)
| Market Cap | 62.31M -26.0% |
| Revenue (ttm) | 10.60M +27.4% |
| Net Income | -11.58M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,000 |
| Open | 0.7000 |
| Previous Close | 0.4735 |
| Day's Range | 0.4735 - 0.7000 |
| 52-Week Range | 0.4500 - 0.7359 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz ... [Read more]
Financial Performance
In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.
Financial numbers in SEK Financial StatementsNews
Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds
UPPSALA, SE / ACCESS Newswire / July 16, 2026 / Senzime AB's (publ) (STO:SEZI)(OTCQX:SNZZF) interim report for April - June (Q2) 2026 is now available on the company's website www.senzime.com. Financi...
Senzime AB Quarterly report: Q2 2026
Senzime AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Senzime AB Slides: Q2 2026
Senzime AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Senzime and Philips Medical Systems Enter Development and Commercialization Partnership
UPPSALA, SE / ACCESS Newswire / July 15, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB announced today that it has entered into a long-term agreement with Philips Electronics Nederland, B.V. thr...
Invitation to Presentations of Senzime's Second Quarter 2026 Report
UPPSALA, SE / ACCESS Newswire / July 13, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to presentations of the second quarter report for 2026 on July 16. The report wil...
Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil
UPPSALA, SE / ACCESS Newswire / June 29, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) announced today that the TetraGraph system has received approval from the Brazilian Health Regulatory Agency (ANVISA), e...
Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026
UPPSALA, SE / ACCESS Newswire / June 5, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF), a global leader in precision-based patient monitoring, today announced the launch of TetraAnalytics™, a new data anal...
Senzime Strengthens Position in Pediatric Anesthesia by Securing Another Hospital Contract and Highlighting Positive Outcome Data
UPPSALA, SE / ACCESS Newswire / June 3, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) announced today advancements within pediatric anesthesia, securing another top ranked pediatric hospital contract. The...
Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor
UPPSALA, SE / ACCESS Newswire / June 1, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) today announced the launch of its latest TetraSens® EMG sensor for use with the TetraGraph® Train-of-Four monitoring s...
From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System
UPPSALA, SE / ACCESS Newswire / May 27, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that its TetraGraph® neuromuscular monitoring system has received an additional FDA Class II...
Bulletin From Annual General Meeting in Senzime AB (publ)
UPPSALA, SE / ACCESS Newswire / May 19, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - The annual general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the "Company") was held on 19 May 2026 at ...
Senzime Strengthens U.S. Operations with New Leadership Appointments
UPPSALA, SE / ACCESS Newswire / April 29, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced new appointments to its Global Executive Leadership Team, including the recruitment of a n...
Senzime's TetraGraph System Contracted on Three Leading GPO Agreements in the US
UPPSALA, SE / ACCESS Newswire / April 24, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that the TetraGraph System has secured inclusion in agreements with Vizient, Premier, and ...
Senzime Publishes Annual and Sustainability Report for 2025
UPPSALA, SE / ACCESS Newswire / April 24, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) announces today that the company's annual and sustainability report for 2025 is published and avail...
Margins Strengthened and Cash Flow Improved Despite a Temporary Dip in The Growth Trajectory. Full-Year Targets Remain on Track
UPPSALA, SE / ACCESS Newswire / April 22, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2026 is now available on the company's website www.senzime.co...
Senzime AB Quarterly report: Q1 2026
Senzime AB has published its Q1 2026 quarterly earnings report on April 22, 2026.
Senzime AB Slides: Q1 2026
Senzime AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Senzime Wins Expanded Contract Within Leading Southeastern US Hospital System
UPPSALA, SE / ACCESS Newswire / April 20, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that it has expanded its agreements with a leading hospital system (IDN) with network in t...
Notice of Annual General Meeting in Senzime AB (publ)
UPPSALA, SE / ACCESS Newswire / April 17, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - The shareholders in Senzime AB (publ) corp. reg. no 556565-5734 (the "Company") are hereby convened to an annual gene...
Invitation to Presentations of Senzime's First Quarter 2026 Report
UPPSALA, SE / ACCESS Newswire / April 17, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to presentations of the first quarter report for 2026 on April 22. The...
Senzime Secures Strategic Hospital Orders Within Leading US Integrated Healthcare Delivery Network
UPPSALA, SE / ACCESS Newswire / April 9, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that it has secured strategic contracts to supply hospitals within one of the world's large...
Senzime Launches TetraCom Connectivity Platform Enabling Universal Transmission of Anesthesia Data
UPPSALA, SE / ACCESS Newswire / February 19, 2026 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) today announced the launch of the TetraCom TM hospital connectivity platform. TetraCom is a first of its k...
Senzime Secures Credit Line Facility of 50 MSEK
UPPSALA, SE / ACCESS Newswire / February 18, 2026 / Senzime AB (publ.) (STO:SEZI)(OTCQX:SNZZF) announces that the company has secured a credit line facility of 50 MSEK.
Senzime Q4 2025: Accelerated Growth and Continued Clear Path to Profitability
UPPSALA, SE / ACCESS Newswire / February 18, 2026 / Senzime AB's (publ.) (STO:SEZI)(OTCQX:SNZZF) year-end report for January - December 2025 is now available on the company's website www.senzime.com.
Senzime AB Earnings Call Transcript: Q4 2025
Revenue grew 90% in constant currencies for 2025, with Q4 revenues more than doubling year-over-year. Gross margin and EBITDA improved, while operating expenses remained stable. Positive cash flow is targeted for Q4 2026, supported by strong global growth and new product launches.